Beloit, Foxconn, Shine, MVI, & More: This Week’s Wisconsin Watchlist
(Page 2 of 2)
based on positive initial findings from its Phase 1b study, the company will now dose 20 prostate cancer patients with MVI-816 and pembrolizumab for up to 48 weeks.
—Moxe Health, a Madison-based startup developing digital tools to help facilitate the flow of patient data between healthcare providers, insurers, and software applications, introduced a new product suite that’s ultimately aimed at helping providers identify gaps in care and improve patient outcomes. The suite, known as Convergence, allows networks of hospitals and clinics to exchange different types of patient health information with health plans. Moxe said that one module within Convergence helps users pull together clinical documentation, claims sent to insurers, medication data, and other information—all within a single software application.